Gilead Buys Its Third Priority Review Voucher, But Is The Mania Over?
Executive Summary
Just as the tulip craze eventually subsided, it appears the pharma industry's infatuation with priority review vouchers also may be waning, as Sarepta sells its voucher for only $125m.
You may also be interested in...
Deals Of The Year: Cast Your Vote For Top Financing Of 2017
It's time for In Vivo's 10th annual Deals of the Year contest. We've selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners. (It's free.)
Proceeds From Chagas Treatment Priority Review Voucher Will Help Ensure Access
US FDA approved its first treatment for the tropical disease and awarded a priority review voucher that will be sold as per agreement between development partners.
Keeping Track: Tremfya Clears FDA; Dextenza Amendment Is Too Late; Emicizumab, Abemaciclib Filed
The latest drug development news and highlights from our US FDA Performance Tracker.